EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review

Zahra Oskouei, Mohammad Moshiri, Amene Raouf-Rahmati, Ahmad Nemati, Mehri Bemani Naeini, Hamid Jomehpour, Ali Roohbakhsh, Zahra Salmasi, Leila Etemad

Addiction and Health · 2025

DOI: 10.34172/ahj.1527 ↗
AbstractBibliografische Angaben

Abstract

Background: Pregabalin (PGB), a gabapantinoid drug, which is commonly prescribed by physicians and some patients abuse it, can lead to seizure. Pregabalin-induced seizures (PGBIS) and their risk factors were systematically reviewed. Methods: The databases were searched from January 1, 2011, to August 1, 2022. Studies that reported PGBIS were included. The records were assessed according to the PRISMA-P protocol. Results: From a total of 224 records, 11 studies were included, comprising four cross-sectional studies and seven case reports. The data from the cross-sectional studies were notably limited. Seven studies documented nine cases (five females and four males), with a median age of 51 years (ranging from 16 to 65). PGB was used for therapeutic purposes, abuse, and suicide attempts. One case had kidney dysfunction. A significant number of cases used PGB with other drugs. There was no difference between the ingested dose of PGB in men (2700 and 4200 mg) and women (3000, 1200, 3825, and 1200 mg). All cases had normal renal function, except for one case. Conclusion: PGBIS is not common. However, it was reported for all purposes of PGB consumption. No specific risk factor for PGBIS was found. It was more commonly reported in females, patients who consumed high doses of PGB (>1200 mg), patients who ingested multiple drugs, and patients with renal insufficiency. The dosages used for therapeutic purposes were much lower than in the other two groups.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →